Dipeptidyl Peptidase-4 Inhibitor

Known as: DPP-4 Inhibitor 
Any inhibitor of the proline-specific serine protease dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity. DPP-4 inhibitors bind to DPP-4 and… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2003-2017
05010015020032017

Related topics

Related topics

3 relations
Dipeptidyl Peptidase 4 Inhibitor [EPC]Dipeptidyl Peptidase 4 Inhibitors [MoA]Dipeptidyl-Peptidase IV Inhibitors

Related mentions per year

Related mentions per year

1978-2018
197019801990200020102020
Dipeptidyl Peptidase-4 Inhibitor
Dipeptidyl-Peptidase IV Inhibitors
Dipeptidyl Peptidase 4 Inhibitors [MoA]
Dipeptidyl Peptidase 4 Inhibitor [EPC]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Cardioprotective effect of dipeptidyl peptidase-4 inhibitor during ischemia-reperfusion injury.
BACKGROUND Dipeptidyl peptidase-4 (DPP-4) inhibitor is a new anti-diabetic drug for type-2 diabetes mellitus patients. Despite… (More)
Is this relevant?
Highly Cited
2012
Highly Cited
2012
A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice.
OBJECTIVES The aim of this study was to investigate the antiatherogenic effects of the dipeptidyl peptidase-4 inhibitor, des… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin(*).
AIM This study assessed the influence of various degrees of renal impairment on the exposure of linagliptin, a dipeptidyl… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Is this relevant?
Highly Cited
2010
Highly Cited
2010
The Oral Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Increases Circulating Endothelial Progenitor Cells in Patients With Type 2 Diabetes
OBJECTIVE Vasculoprotective endothelial progenitor cells (EPCs) are regulated by stromal-derived factor-1alpha (SDF-1alpha) and… (More)
  • figure 1
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension.
The effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on ambulatory blood pressure was assessed in nondiabetic patients… (More)
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes.
OBJECTIVE To assess the efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2… (More)
  • figure 1
  • table 3
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes.
OBJECTIVE Sitagliptin, an oral, potent, and selective dipeptidyl peptidase-4 (DPP-4) inhibitor was evaluated as once-daily… (More)
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
AIM To assess the efficacy and safety of a 24-week treatment with sitagliptin, a highly selective once-daily oral dipeptidyl… (More)
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus
The aim of this study was to assess the efficacy and safety of sitagliptin (MK-0431) as monotherapy in patients with type 2… (More)
  • table 1
  • table 1
  • figure 1
  • table 2
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
OBJECTIVE The efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, added to ongoing metformin therapy, were… (More)
  • table 1
  • figure 1
  • table 2
Is this relevant?